Then, gene regulatory difference between the predicted type I and type II TF binding sites was investigated in two human ChIP-seq experiments, the estrogen receptor α (ESR1) using the MCF7 breast cancer cell line and the SPIB TF using the HBL1 activated B cell-like diffuse large B-cell lymphoma (ABC DLBCL) cell line. This evidence concerns the gene SPIB and breast cancer.